Home | Contact Us

Roskamp Institute Patients, Families and Friends Healthcare Professionals Clinical Operations
Roskamp Institute
About Us How to Help News Careers PhD Program Better science. Real discovery.

Anti-inflammatory effects of RCP006

The Roskamp Institute is interested in finding new treatments for the diseases of aging associated with chronic inflammation. In this respect Roskamp Institute scientists are examining the properties of RCP006 whose active ingredient is anatabine. In further studies of NF-KB activity and anatabine's ability to decrease it, we see that LPS induced NF-KB activation in human white blood cells is decreased at dose equivalents to aspirin or celebrex (which is toxic at these doses).

In this experiment Peripheral blood mononuclear cells were isolated using ficoll paque method, as per manufacturer’s instructions. The cells were activated with LPS 10μg/ml and treated with 1.25mM Anatabine, Celebrex or Aspirin. Cells were incubated at 37°C and 5% CO2 with the above treatments overnight (18hrs) in RPMI media supplemented with 20mg/ml of PHA, 1% penstrep and 1% glutamax.

Top | Home




Inflammaging research at the Roskamp Institute